GDRX Earnings Date: Nov 3, 2026 (Estimated) — GoodRx Holdings, Inc.
NASDAQ · Healthcare · Health Information Services
Updated
When is GDRX's next earnings date?
GoodRx Holdings, Inc. (GDRX) is expected to report Q3 2026 earnings on Tuesday, November 3, 2026 at 4:00 PM ET (after market close); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of $0.08 on revenue of $202.1M.
How did GDRX do in its last earnings report?
In its most recent report on Aug 5, 2026 (Q2 2026), GoodRx Holdings, Inc. posted EPS of $0.08 versus the $0.08 estimate, a beat of 14.3%. Revenue was $200.4M against a $193.2M estimate. The stock's 1-day post-earnings move was +13.8%.
How much does GDRX stock move after earnings?
GDRX beat EPS estimates in 6 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 11.7% (up or down) in the day after earnings.
About GoodRx Holdings, Inc.
GoodRx Holdings, Inc. provides American consumers with essential resources and tools to compare and ultimately lower the cost of their prescription medications. The company operates a digital platform dedicated to price comparison, delivering customized, geographically tailored prescription pricing. It also grants access to special, negotiated rates through unique GoodRx codes, which can be utilized for savings on prescriptions throughout the entire United States. Beyond this core offering, the firm also extends its portfolio to include subscription services, programs designed for pharmaceutical manufacturers, and telehealth capabilities. GoodRx additionally collaborates with pharmacy benefit managers, entities responsible for managing drug formularies and overseeing prescription transactions, including the critical task of setting prices between consumers and pharmacies. The company was founded in 2015 and maintains its principal office in Santa Monica, California.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-05 | Q2 2026 | 0.08 | 0.08 | +14.29% | $200.4M | ✅ Beat | +13.76% | +9.79% | +7.95% |
| 2026-05-06 | Q1 2026 | 0.06 | 0.07 | +16.67% | $194.0M | ✅ Beat | +10.51% | +1.56% | +3.11% |
| 2026-02-25 | Q4 2025 | 0.07 | 0.09 | +28.57% | $194.8M | ✅ Beat | -18.78% | -11.02% | -16.73% |
| 2025-11-04 | Q3 2025 | 0.07 | 0.08 | +14.29% | $196.0M | ✅ Beat | +2.15% | -7.06% | -15.64% |
| 2025-08-06 | Q2 2025 | 0.08 | 0.09 | +12.50% | $203.1M | ✅ Beat | -20.05% | -17.97% | -7.83% |
| 2025-02-27 | Q4 2024 | 0.10 | 0.09 | -10.00% | $198.6M | ❌ Miss | +1.84% | +1.02% | -7.57% |
| 2024-11-07 | Q3 2024 | 0.09 | 0.08 | -11.11% | $195.3M | ❌ Miss | -17.51% | -23.73% | -19.64% |
| 2024-05-09 | Q1 2024 | 0.07 | 0.08 | +14.29% | $197.9M | ✅ Beat | -8.94% | -4.47% | +12.35% |
Showing last 8 quarters.
Revenue by segment & region
By segment
Q2 FY26 · $138.8M total
| Segment | Share | Revenue | YoY | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 |
|---|---|---|---|---|---|---|---|
| Prescription Transactions Revenue | 76.7% | $106.4M | -25.6% | $140.4M | $291.7M | $148.9M | $143.1M |
| Subscription Revenue | 20.5% | $28.5M | +39.3% | $21.3M | $42.6M | $21.0M | $20.5M |
| Other Revenue | 2.8% | $3.9M | -15.0% | $5.4M | $10.2M | $4.4M | $4.6M |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.